TNFRSF19抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using TNFRSF19 mouse mAb (green) and negative control (red).    

  
  

The TNFRSF19 (tumor necrosis factor receptor superfamily member 19) antibody is a research tool targeting the TNFRSF19 protein, a member of the TNF receptor superfamily involved in regulating apoptosis, cell proliferation, and immune responses. TNFRSF19. also known as TROY or TAJ, is a type I transmembrane protein characterized by cysteine-rich extracellular domains and a cytoplasmic death domain. It plays roles in developmental processes, tissue homeostasis, and nervous system regulation, though its precise mechanisms remain under investigation. Studies suggest it interacts with ligands like lymphotoxin-alpha and may activate NF-κB or Wnt signaling pathways, depending on cellular context.

TNFRSF19 is implicated in cancer (e.g., colorectal, lung) and neurodegenerative diseases. Its overexpression in certain tumors correlates with poor prognosis, potentially promoting invasiveness or therapy resistance. In neuroscience, it regulates neural stem cell maintenance and differentiation. Antibodies against TNFRSF19 are used to study its expression, localization, and function. Monoclonal and polyclonal variants enable applications like Western blotting, immunohistochemistry, and flow cytometry. Therapeutically, these antibodies are explored for blocking ligand-receptor interactions or modulating signaling in preclinical models. Challenges include understanding context-dependent signaling and optimizing specificity. Current research focuses on clarifying its dual roles in apoptosis/pro-survival pathways and validating its utility as a diagnostic or therapeutic target.